Eradication of Helicobacter pylori: are rifaximin-based regimens effective?
Author(s): Gasbarrini A, Gasbarrini G, Pelosini I, Scarpignato C Affiliation(s): Department of Internal Medicine, Gemelli University Hospital, Catholic University of Sacred Heart, Rome, Italy. agasbarrini@rm.unicatt.it Publication date & source: 2006, Digestion., 73 Suppl 1:129-35. Epub 2006 Feb 8. Publication type: Review Rifaximin is a non-absorbed semisynthetic rifamycin derivative with a broad spectrum of antibacterial activity including Gram-positive and Gram-negative bacteria, both aerobes and anaerobes. Although originally developed for the treatment of infectious diarrhea, the appreciation of the pathogenic role of gut bacteria in several organic and functional gastrointestinal diseases has increasingly broadened its clinical use. Being the antibiotic active against Helicobacter pylori, even towards clarithromycin-resistant strain, and being the primary resistance very rare, several investigations explored its potential use for eradication of the microorganism. Rifaximin alone
